SGT-53 in Children With Recurrent or Progressive CNS Malignancies

Stopped The grant intended to support this trial as ultimately not funded. This trial was not initiated,. No patients were enrolled.

Conditions

• Childhood CNS Tumor

Interventions

• GENETIC: SGT-53
• RADIATION: Radiation
• DRUG: Irinotecan
• DRUG: Temozolomide
• DRUG: Bevacizumab

Sponsor

SynerGene Therapeutics, Inc.